Literature DB >> 18588522

Recommendations for the treatment of established fungal infections.

K A Thursky1, E G Playford, J F Seymour, T C Sorrell, D H Ellis, S D Guy, N Gilroy, J Chu, D R Shaw.   

Abstract

Evidence-based guidelines for the treatment of established fungal infections in the adult haematology/oncology setting were developed by a national consensus working group representing clinicians, pharmacists and microbiologists. These updated guidelines replace the previous guidelines published in the Internal Medicine Journal by Slavin et al. in 2004. The guidelines are pathogen-specific and cover the treatment of the most common fungal infections including candidiasis, aspergillosis, cryptococcosis, zygomycosis, fusariosis, scedosporiosis, and dermatophytosis. Recommendations are provided for management of refractory disease or salvage therapies, and special sites of infections such as the cerebral nervous system and the eye. Because of the widespread use newer broad-spectrum triazoles in prophylaxis and empiric therapy, these guidelines should be implemented in concert with the updated prophylaxis and empiric therapy guidelines published by this group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588522     DOI: 10.1111/j.1445-5994.2008.01725.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  10 in total

1.  Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.

Authors:  G Maschmeyer; W J Heinz; B Hertenstein; H-A Horst; C Requadt; T Wagner; O A Cornely; J Löffler; M Ruhnke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-28       Impact factor: 3.267

2.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.

Authors:  Bharat Damle; Manthena V Varma; Nolan Wood
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

4.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.

Authors:  Catherine Cordonnier; Montserrat Rovira; Johan Maertens; Eduardo Olavarria; Catherine Faucher; Karin Bilger; Arnaud Pigneux; Oliver A Cornely; Andrew J Ullmann; Rodrigo Martino Bofarull; Rafael de la Cámara; Maja Weisser; Effie Liakopoulou; Manuel Abecasis; Claus Peter Heussel; Marc Pineau; Per Ljungman; Hermann Einsele
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

5.  Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).

Authors:  Madhu Rengasamy; Manjunath M Shenoy; Sunil Dogra; Neelakandhan Asokan; Ananta Khurana; Shital Poojary; Jyothi Jayaraman; Ameet R Valia; Kabir Sardana; Seetharam Kolalapudi; Yogesh Marfatia; P Narasimha Rao; Ramesh M Bhat; Mahendra Kura; Deepika Pandhi; Shyamanta Barua; Vibhor Kaushal
Journal:  Indian Dermatol Online J       Date:  2020-07-13

6.  Determinants of mortality in non-neutropenic ICU patients with candidaemia.

Authors:  Deborah J E Marriott; E Geoffrey Playford; Sharon Chen; Monica Slavin; Quoc Nguyen; David Ellis; Tania C Sorrell
Journal:  Crit Care       Date:  2009-07-13       Impact factor: 9.097

7.  Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.

Authors:  Santirat Prommas; Apichaya Puangpetch; Nuttawut Jenjirattithigarn; Sumonrat Chuwongwattana; Thawinee Jantararoungtong; Napatrupron Koomdee; Siwalee Santon; Montri Chamnanphon; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-24       Impact factor: 2.352

Review 8.  Antifungal drug resistance: do molecular methods provide a way forward?

Authors:  David S Perlin
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

9.  An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.

Authors:  F Jacobs; D Selleslag; M Aoun; A Sonet; A Gadisseur
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-05       Impact factor: 3.267

10.  Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.

Authors:  Huang-Tz Ou; Tsung-Ying Lee; Yee-Chun Chen; Claudie Charbonneau
Journal:  BMC Infect Dis       Date:  2017-07-10       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.